Photo of Peter Chang,  MD, MPH

Peter Chang, MD, MPH

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 667-4075
Fax: (617) 667-7292


pchang@bidmc.harvard.edu

Peter Chang, MD, MPH

Beth Israel Deaconess Medical Center

EDUCATIONAL TITLES

  • Instructor, Surgery, Harvard Medical School
  • Director, Prostate Cancer Care Center, Surgery, Beth Israel Deaconess Medical Center

DF/HCC PROGRAM AFFILIATION

Research Abstract

I am a Urologic Oncologist with a clinical and research focus on prostate cancer. Currently, I am an Instructor in Surgery at Harvard Medical School, and Director of the Prostate Cancer Care Center at the Beth Israel Deaconess Medical Center. I am a leader in the assessment and management of health-related quality of life (HRQOL) using patient-reported outcomes (PROs), and have a particular interest in the adaptation and implementation of PROs to directly improve patient evaluation and communication in clinical practice. I developed the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) with the goal of allowing HRQOL to be assessed using PROs at the point of care. I am a co-leader of the PROST-QA consortium, a multicenter, prospective cohort of 1,201 men treated for localized prostate cancer followed longitudinally for clinical and HRQOL outcomes. My prostate cancer outcomes research focuses on investigating the factors predicting HRQOL after prostate cancer treatment and evaluating HRQOL in the advanced disease setting. As a practicing minimally invasive urologic surgeon, I also study HRQOL and surgical outcomes following minimally invasive kidney cancer and bladder cancer surgery.

Publications

Powered by Harvard Catalyst
  • Gay HA, Sanda MG, Liu J, Wu N, Hamstra DA, Wei JT, Dunn RL, Klein EA, Sandler HM, Saigal CS, Litwin MS, Kuban DA, Hembroff L, Regan MM, Chang P, , Michalski JM. External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life. Int J Radiat Oncol Biol Phys 2017; 98:304-317. PubMed
  • Chang P, Regan MM, Ferrer M, Guedea F, Patil D, Wei JT, Hembroff LA, Michalski JM, Saigal CS, Litwin MS, Hamstra DA, Kaplan ID, Ciezki JP, Klein EA, Kibel AS, Sandler HM, Dunn RL, Crociani CM, Sanda MG, . Relief of Urinary Symptom Burden after Primary Prostate Cancer Treatment. J Urol 2016. PubMed
  • Lee JY, Daignault-Newton S, Heath G, Scarlett S, Sanda MG, Chang P, Regan MM, Michalski JM, Sandler HM, Feng FY, Kuban DA, Zietman AL, Ciezki JP, Kaplan ID, Crociani C, McLaughlin WP, Mantz CA, Finkelstein SE, Suy S, Collins SP, Garin O, Ferrer M, Hamstra DA, Spratt DE. Multinational Prospective Study of Patient-Reported Outcomes After Prostate Radiation Therapy: Detailed Assessment of Rectal Bleeding. Int J Radiat Oncol Biol Phys 2016. PubMed
  • Dovirak O, Mao J, Taylor K, Chang P, Wagner AA. How to Quantify Recovery After Laparoscopic Adrenalectomy: An Assessment of Patient-reported Health-related Quality of Life. Surg Laparosc Endosc Percutan Tech 2016; 26:290-4. PubMed
  • Wagner AA, Cheng PJ, Carneiro A, Dovirak O, Khosla A, Taylor KN, Crociani CM, McAnally KC, Percy A, Dewey LE, Sanda MG, Chang P. Clinical Use of EPIC for Clinical Practice (EPIC-CP) to Assess Patient-Reported Prostate Cancer Quality-of-Life Following Robot-Assisted Radical Prostatectomy. J Urol 2016. PubMed
  • Storås AH, Sanda MG, Boronat OG, Chang P, Patil D, Crociani C, Suarez JF, Cvancarova M, Loge JH, Fosså SD. Erectile Dysfunction and Sexual Problems Two to Three Years After Prostatectomy Among American, Norwegian, and Spanish Patients. Clin Genitourin Cancer 2016; 14:e265-73. PubMed
  • Patel HD, Riffon MF, Joice GA, Johnson MH, Chang P, Wagner AA, McKiernan JM, Trock BJ, Allaf ME, Pierorazio PM. A Prospective, Comparative Study of Quality of Life among Patients with Small Renal Masses choosing Active Surveillance and Primary Intervention. J Urol 2016. PubMed
  • Wolpin S, Halpenny B, Sorrentino E, Stewart M, McReynolds J, Cvitkovic I, Chang P, Berry D. Usability Testing the "Personal Patient Profile-Prostate" in a Sample of African American and Hispanic Men. Comput Inform Nurs 2016. PubMed
  • Quintana L, Ward A, Gerrin SJ, Genega E, Rosen S, Sanda MG, Wagner AA, Chang P, DeWolf WC, Ye H. Gleason Misclassification Rate is Independent of Number of Biopsy Cores in Systematic Biopsy. Urology 2016. PubMed
  • Danzig MR, Chang P, Wagner AA, Allaf ME, McKiernan JM, Pierorazio PM. Active Surveillance for Small Renal Masses: A Review of the Aims and Preliminary Results of the DISSRM Registry. Current Urology Reports 2015; 17:4. PubMed
  • Danzig MR, Ghandour RA, Chang P, Wagner AA, Pierorazio PM, Allaf ME, McKiernan JM. Active Surveillance is Superior to Radical Nephrectomy and Equivalent to Partial Nephrectomy for Preserving Renal Function in Patients with Small Renal Masses: Results from the DISSRM Registry. J Urol 2015. PubMed
  • Althaus AB, Dovirak O, Chang P, Taylor KN, O'Halloran TD, Wagner AA. Aspirin and clopidogrel during robotic partial nephrectomy, is it safe? Can J Urol 2015; 22:7984-9. PubMed
  • Carneiro A, Sasse AD, Wagner AA, Peixoto G, Kataguiri A, Neto AS, Bianco BA, Chang P, Pompeo AC, Tobias-Machado M. Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis. World J Urol 2015; 33:1281-9. PubMed
  • Pierorazio PM, Johnson MH, Ball MW, Gorin MA, Trock BJ, Chang P, Wagner AA, McKiernan JM, Allaf ME. Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry. Eur Urol 2015. PubMed
  • Chen RC, Chang P, Vetter RJ, Lukka H, Stokes WA, Sanda MG, Watkins-Bruner D, Reeve BB, Sandler HM. Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials. Journal of the National Cancer Institute 2014. PubMed
  • Chipman JJ, Sanda MG, Dunn RL, Wei JT, Litwin MS, Crociani CM, Regan MM, Chang P, . Measuring and predicting prostate cancer related quality of life changes using EPIC for clinical practice. J Urol 2014; 191:638-45. PubMed
  • Chang P, Szymanski KM, Dunn RL, Chipman JJ, Litwin MS, Nguyen PL, Sweeney CJ, Cook R, Wagner AA, DeWolf WC, Bubley GJ, Funches R, Aronovitz JA, Wei JT, Sanda MG. Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer. J Urol 2011; 186:865-72. PubMed
Hide